|Bid||65.80 x 1200|
|Ask||66.26 x 1100|
|Day's range||65.72 - 66.29|
|52-week range||53.63 - 71.70|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1.45 (2.19%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it. Compared to the broader market's slump of around 5% in the last 12 months, AstraZeneca's (NASDAQ: AZN) stock has climbed 19%, making it a robust outperformer, to say the least. The company's success during the bear market is simply a matter of the strength of its drug development pipeline; with 184 projects in clinical trials and late-preclinical testing, it's among the largest in the world.
The board of AstraZeneca PLC ( LON:AZN ) has announced that it will be paying its dividend of $0.764 on the 12th of...
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.